The combination of afatinib and bevacizumab in chemo-naïve EGFR-mutated advanced lung cancer was investigated in a previous study (Okayama Lung Cancer Study Group Trial 1404), but that study was focused on the feasibility of this combination, not its efficacy [21]. Here, EGFR is linked to lung carcinoma.